These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23815697)

  • 21. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
    BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
    Kieback DG; Harbeck N; Bauer W; Hadji P; Weyer G; Menschik T; Hasenburg A
    Gynecol Oncol; 2010 Dec; 119(3):500-5. PubMed ID: 20832103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in the endometrium in treatment of breast carcinoma with tamoxifen].
    Reslová T; Tosner J; Vávrová I; Resl M
    Ceska Gynekol; 1997 Oct; 62(5):277-9. PubMed ID: 9600168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Morphologic endometrium changes with tamoxifen].
    Dallenbach-Hellweg G; Hahn U; Schmidt D
    Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study of the endometrial pathology using flexible ambulatory hysteroscopy of patients treated with Tamoxifen].
    Kuzmanov B
    Akush Ginekol (Sofiia); 2004; 43(3):32-3. PubMed ID: 15341254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
    Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
    J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer.
    López DM; Fernández YG; Sánchez AV; Alvarez MI; Reynaldo MI; Delgado RC
    Menopause; 2013 Jan; 20(1):64-71. PubMed ID: 22968254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
    Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
    AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of raloxifene on other organs without bone: uterus].
    Nozaki M
    Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients].
    Negoiţă M; Mihailovici MS
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):834-8. PubMed ID: 22046795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
    Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
    Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
    Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
    Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study.
    Achiron R; Lipitz S; Sivan E; Goldenberg M; Horovitz A; Frenkel Y; Mashiach S
    Ultrasound Obstet Gynecol; 1995 Aug; 6(2):116-20. PubMed ID: 8535913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of influencing factors of endometrial disease of patients with breast cancer after operation].
    Pan NP; Zhou WX; Tang J; Zhou JH; Li JQ
    Zhonghua Fu Chan Ke Za Zhi; 2019 Dec; 54(12):848-853. PubMed ID: 31874475
    [No Abstract]   [Full Text] [Related]  

  • 36. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen-induced uterine abnormalities: the role of imaging.
    Ascher SM; Imaoka I; Lage JM
    Radiology; 2000 Jan; 214(1):29-38. PubMed ID: 10644098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
    Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
    Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathology of the endometrium in breast cancer patients treated with tamoxifen (nolvadex)].
    Ivanova V; Karaivanov M; Marinov E; Gorchev G; Velkova A; Khristova P
    Akush Ginekol (Sofiia); 2003; 42(5):3-8. PubMed ID: 14682005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.